Alternatives to Tesamorelin If You Can't Fill Your Prescription

Tesamorelin (Egrifta SV, Egrifta WR) is the only FDA-approved medication in the United States for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. But what happens when you can't get it — because it's not covered by your insurance, the prior authorization was denied, it's out of stock at your specialty pharmacy, or it's simply too expensive? In this article, we walk through the alternatives that your doctor might consider.

Important: Never switch or discontinue a prescription medication without talking to your doctor first. This guide is for educational purposes — always work with your prescribing physician to find the right treatment for your individual situation.

Why Tesamorelin Has No Perfect Substitute

Tesamorelin is unique because it is the only FDA-approved drug for HIV-associated lipodystrophy specifically. It works by stimulating the pituitary gland to release growth hormone, which in turn reduces visceral fat — the hard belly fat that accumulates in people living with HIV who develop lipodystrophy. No other drug has gone through the Phase 3 clinical trials required to earn this specific FDA approval. That said, several options exist that doctors may consider when tesamorelin is unavailable or not an option.

Option 1: Sermorelin (Compounded, Off-Label)

Sermorelin is a growth hormone-releasing hormone (GHRH) analog containing the first 29 amino acids of human GHRH. Like tesamorelin, it stimulates the pituitary gland to release growth hormone — but it is shorter, has a shorter half-life (about 10 to 20 minutes versus 30 to 60 minutes for tesamorelin), and produces a gentler GH response.

The original branded sermorelin product (Geref) was discontinued in 2008, but sermorelin remains available through licensed 503A and 503B compounding pharmacies. It is not FDA-approved for adult use or for HIV lipodystrophy — this would be off-label prescribing. However, it is significantly less expensive, typically $300 to $800 per month at compounding pharmacies versus $2,400 to $2,800 per month for brand-name Egrifta. Clinical evidence for sermorelin specifically in HIV lipodystrophy is limited compared to tesamorelin's Phase 3 data.

Option 2: Somatropin (Recombinant Human Growth Hormone)

Somatropin (sold under brand names like Genotropin, Norditropin, Humatrope, and others) is recombinant human growth hormone (rhGH). Unlike tesamorelin — which stimulates your body to make its own GH — somatropin directly replaces growth hormone. It is FDA-approved for growth hormone deficiency in adults and for HIV wasting syndrome, though not specifically for HIV lipodystrophy visceral fat reduction.

Somatropin has been studied in HIV lipodystrophy and can reduce visceral fat, but it comes with greater risks than tesamorelin, including insulin resistance, joint pain, and carpal tunnel syndrome. It also tends to be very expensive. Some HIV specialists may use it as an alternative in patients who cannot access tesamorelin, though this is less common today.

Option 3: Ipamorelin (Compounded, Off-Label)

Ipamorelin is a growth hormone-releasing peptide (GHRP) that stimulates GH release through a different mechanism — it mimics ghrelin rather than GHRH. It is sometimes combined with a GHRH analog like sermorelin or CJC-1295 in off-label body composition protocols. Ipamorelin is not FDA-approved for any indication and is only available through compounding pharmacies. Evidence for its use in HIV lipodystrophy is observational and limited.

Option 4: Antiretroviral Therapy Modification

HIV-associated lipodystrophy is often caused or worsened by specific antiretroviral medications, particularly older protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs). Switching to newer antiretroviral regimens that are less associated with lipodystrophy — such as integrase strand transfer inhibitor (INSTI)-based regimens — can reduce or prevent further fat accumulation. This approach works best when done early and must be discussed carefully with your HIV specialist, as maintaining viral suppression is the top priority.

Option 5: Dietary Changes and Exercise

HIV lipodystrophy-related visceral fat can be very resistant to diet and exercise alone. Clinical studies show that diet and aerobic exercise produce modest results in reducing visceral fat in HIV patients compared to tesamorelin. However, lifestyle modifications are important as a foundation for any treatment plan and may help slow fat accumulation even if they cannot reverse it on their own.

Compounded Tesamorelin: Is It an Option?

Compounded tesamorelin is available from 503A and 503B compounding pharmacies at a significantly lower cost than brand-name Egrifta — typically $150 to $1,200 per month depending on the pharmacy type and dosage. Compounded tesamorelin contains the same active peptide as Egrifta but is not FDA-approved and is not covered by insurance. The FDA has raised concerns about compounded peptides in the past, so discuss this option carefully with your doctor before pursuing it. It is never appropriate to purchase tesamorelin from online sources that do not require a prescription.

Before Giving Up on Tesamorelin: Try These Access Options

Before switching to an alternative, make sure you have explored all access pathways for tesamorelin itself. Use medfinder to find pharmacies that can fill your prescription, call the THERA Patient Support line (1-833-23-THERA), and see our guide on how to save money on tesamorelin — including the manufacturer's patient assistance program that provides the medication at no cost for qualifying patients.